Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Lung Neoplasms
  • Mutation
  • Phosphatidylinositol 3-Kinases
  • Protein Kinase Inhibitors
  • Receptor, Epidermal Growth Factor

abstract

  • A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas. There was no evidence that clinical benefit from EGFR TKI monotherapy is affected by a concurrent PIK3CA mutation in EGFR-mutant lung cancers.

publication date

  • December 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4760768

Digital Object Identifier (DOI)

  • 10.1097/JTO.0000000000000671

PubMed ID

  • 26334752

Additional Document Info

start page

  • 1713

end page

  • 9

volume

  • 10

number

  • 12